Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations.

This prospective, single-arm, open-label, multicenter, dose-escalation, phase I study (ClinicalTrials.gov identifier NCT05458180 ... Cardiac toxicities of any grade were reported as palpitation (7.7%) ...

Rather than targeting a single drug candidate ... Petosemtamab is being evaluated in multiple Phase 1/2 trials, exploring its potential both as a monotherapy and in combination settings.

This letter proposes a novel waveform design for joint sensing and communication (JSAC) systems, combining single-carrier interleaved frequency division multiplexing ... and a cyclic prefix (CP) is ...

School of Physics and Wuhan National High Magnetic Field Center, Huazhong University of Science and Technology, Wuhan 430074, China ...